OraSure Technologies Inc
NASDAQ:OSUR
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
OraSure Technologies Inc
NASDAQ:OSUR
|
229.8m USD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
9.4T JPY |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
55.7B USD |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
30.6B CHF |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
100.8B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12B USD |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
42.6B CNY |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6.2B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.6B GBP |
Loading...
|
|
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.2B USD |
Loading...
|
|
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
818.8B JPY |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
OraSure Technologies Inc
Glance View
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. The company is headquartered in Bethlehem, Pennsylvania and currently employs 785 full-time employees. The firm's products include molecular sampling kits for the genome and microbiome services and analytics, rapid diagnostics for infectious disease, and tests for substance abuse. OraSure’s segments include Diagnostics segment and Molecular Collection Systems segment. The Diagnostics business primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices. The Molecular Solutions business consists of the manufacture and sale of kits that are used to collect, stabilize, transport and store biological samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbiome and animal genetics markets.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for OraSure Technologies Inc is 40.4%, which is below its 3-year median of 41.9%.
Over the last 3 years, OraSure Technologies Inc’s Gross Margin has increased from 38.3% to 40.4%. During this period, it reached a low of 38.1% on Dec 31, 2022 and a high of 44.6% on Jun 30, 2024.
